Fluidigm, Kips Bay close IPOs | Funding roundup

Microfluidics company Fluidigm Corp. (NSDQ:FLDM) and medical device developer Kips Bay Medical Inc. (NSDQ:KIPS) both went public late last week.

San Francisco-based Fluidigm priced its offering of about 5.6 million shares of its common stock at $13.50 per share — the bottom of its range — and raised $75 million.

The company’s share price has increased more than 6 percent over the offering amount and reached about $14.45 in late afternoon trading today.

Minneapolis-based Kips priced its offering of about 2.1 million shares of its common stock at $8.00 per share — also the bottom of its range — and raised $17 million.

After declining about 1 percent in their opening week, KIPS shares have since recovered and were going for around $8.00 in late afternoon trading today.

The company is planning to support the U.S. regulatory process for its vascular mesh with the new funding.

Here’s a roundup of the latest dealflow and investment news:

• Varian board authorizes repurchase of additional 12 million shares through fiscal 2012
  Varian Medical Systems Inc. (NYSE:VAR) today announced that its Board of Directors has authorized the company to repurchase an additional 12 million shares of its common stock through the end of its fiscal year 2012. Stock repurchases may be made in the open market, in privately negotiated transactions (including accelerated share repurchase programs), or in Rule 10b5-1 share repurchase plans, and may be made from time to time or in one or more larger blocks. These repurchases are in addition to the approximately 4.5 million shares remaining under an 8 million share repurchase authorization that expires at the end of the company’s fiscal year 2011.
  Read more
• Thermo Fisher Scientific announces debt offering
  Thermo Fisher Scientific Inc. (NYSE:TMO) intends to offer senior notes to fund its acquisition of Dionex Corporation, as well as for general corporate purposes. The aggregate purchase price of the Dionex acquisition, which was announced separately by the company, is estimated to be approximately $2.1 billion. The joint book-running managers for the offering are Barclays Capital Inc. and J.P. Morgan Securities LLC.
  Read more
• Sonoma Orthopedic Products closes $22 million Series D financing
  Sonoma Orthopedic Products closed a $22 million Series D financing round led by Ascension Health Ventures (AHV). Also participating in the round were Split Rock Partners, Legacy Life Sciences, EDF Ventures, MedVenture Associates, DFJ InCube Ventures, Emergent Medical Partners, and Asset Management Partners. In connection with the financing, Dr. Walter Lin of AHV has joined Sonoma’s board of directors. Sonoma is a commercial orthopedic trauma company focused on minimally invasive repair of fractured bone through its proprietary implant technology. The financing will support several new product launches, expansion of the U.S. sales network, key clinical trials, and the acquisition of certain key assets of NovaLign Orthopaedics Inc.
  Read more
• MedQuist Holdings closes of IPO and scquisition of sdditional shares of MedQuist Inc.
  MedQuist Holdings Inc. (NSDQ:MEDH), formerly CBaySystems Holdings Limited, a leading provider of integrated clinical documentation solutions for the U.S. healthcare system, today announced the closing of the initial public offering of shares of its common stock. MEDH shares began trading on Feb. 4. In the offering, MedQuist Holdings Inc. sold 3,000,000 shares, and selling stockholders sold 2,175,000 shares, including 675,000 shares sold pursuant to the overallotment option, which was exercised in full by the underwriters.
  Read more
• Elenza drums up $24 million in Series B round
  Elenza Inc. (formerly Ocular Optics) raised $24 million in Series B financing from The Carlyle Group, Delphi Ventures and from new investors ITOCHU Corp. and an undisclosed strategic corporate investor from the ophthalmic industry. The company plans to finance clinical development and technology commercialization of its Electro-active AutoFocal Intraocular Lens for the cataract extraction market and future opportunities related to presbyopia. Elenza also plans to fund clinical and regulatory activities for obtaining CE mark approval in Europe.
  Read more
• Arsanis drums up $9.6 million
  Lebanon, N.H.-based biotech firm Arsanis Inc. closed a $9.6 million equity-based financing round from seven unnamed investors, according to a document filed with the Securities & Exchange Commission. One of the company’s executives listed on the filing is Tillman Gerngross, the co-founder and CEO of the Lebanon-based antibody discovery firm Adimab, reported Xconomy Boston.
  Read more